Clinical Trial Details
Trial ID: | L4242 |
Source ID: | NCT03462017 |
Associated Drug: | Sar247799 |
Title: | Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus |
Acronym: | |
Status: | COMPLETED |
Study Results: | NO |
Results: | |
Conditions: | Microvascular Coronary Artery Disease |
Interventions: | DRUG: SAR247799|DRUG: Placebo|DRUG: Sildenafil|DRUG: Acetylcholine |
Outcome Measures: | Primary: Change in Flow Mediated Dilation (FMD), Absolute change from baseline in the % FMD index of the brachial artery, Baseline to Days 14, 21, 28, 35, and 42 | Secondary: Microvascular reactivity, Change from baseline in peak flow induced by acetylcholine iontophoresis measured using Laser Doppler perfusion monitoring, Baseline to Days 14, 21, 28, 35, and 42|Number of adverse events, Number of participants with adverse events, Up to Day 42|Assessment of pharmacokinetic (PK) parameter: Cmax, Cmax: Maximum plasma concentration observed, Days 1, 2, 3, 7, and 14|Assessment of PK parameter: Ctrough, Ctrough: Plasma concentration observed just before treatment administration during repeated dosing, Days 1, 2, 3, 7, and 14|Assessment of PK parameter: tmax, tmax: Time to reach Cmax, Days 1, 2, 3, 7, and 14|Assessment of PK parameter: AUC0-24, AUC0-24: Area under the plasma concentration versus time curve over the dosing interval (24h), Days 1, 2, 3, 7, and 14 |
Sponsor/Collaborators: | Sponsor: Sanofi |
Gender: | ALL |
Age: | ADULT |
Phases: | PHASE1 |
Enrollment: | 54 |
Study Type: | INTERVENTIONAL |
Study Designs: | Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE |
Start Date: | 2018-03-07 |
Completion Date: | 2018-12-22 |
Results First Posted: | |
Last Update Posted: | 2022-04-25 |
Locations: | Investigational Site Number 2760002, Mainz, 55116, Germany|Investigational Site Number 2760001, Neuss, 41460, Germany |
URL: | https://clinicaltrials.gov/show/NCT03462017 |